• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

微小 RNA-26a 在黑色素瘤中强烈下调,并通过抑制死亡结构域沉默子(SODD)诱导细胞死亡。

MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD).

机构信息

Department of Dermatology, University of Colorado Denver School of Medicine, Aurora, Colorado 80045, USA.

出版信息

J Invest Dermatol. 2013 May;133(5):1286-93. doi: 10.1038/jid.2012.400. Epub 2012 Nov 29.

DOI:10.1038/jid.2012.400
PMID:23190898
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3898712/
Abstract

Melanoma is an aggressive cancer that metastasizes rapidly and is refractory to conventional chemotherapies. Identifying microRNAs (miRNAs) that are responsible for this pathogenesis is therefore a promising means of developing new therapies. We identified miR-26a through microarray and quantitative reverse-transcription-PCR (qRT-PCR) experiments as an miRNA that is strongly downregulated in melanoma cell lines as compared with primary melanocytes. Treatment of cell lines with miR-26a mimic caused significant and rapid cell death compared with a negative control in most melanoma cell lines tested. In surveying targets of miR-26a, we found that protein levels of SMAD1 (mothers against decapentaplegic homolog 1) and BAG-4/SODD were strongly decreased in sensitive cells treated with miR-26a mimic as compared with the control. The luciferase reporter assays further demonstrated that miR-26a can repress gene expression through the binding site in the 3' untranslated region (3'UTR) of SODD (silencer of death domains). Knockdown of these proteins with small interfering RNA (siRNA) showed that SODD has an important role in protecting melanoma cells from apoptosis in most cell lines sensitive to miR-26a, whereas SMAD1 may have a minor role. Furthermore, transfecting cells with a miR-26a inhibitor increased SODD expression. Our findings indicate that miR-26a replacement is a potential therapeutic strategy for metastatic melanoma, and that SODD, in particular, is a potentially useful therapeutic target.

摘要

黑色素瘤是一种侵袭性癌症,其转移迅速且对传统化疗具有抗药性。因此,确定导致这种发病机制的 microRNAs (miRNAs) 是开发新疗法的一种有前途的方法。我们通过微阵列和定量逆转录-PCR (qRT-PCR) 实验发现 miR-26a 是一种 miRNA,与原代黑素细胞相比,在黑色素瘤细胞系中强烈下调。与大多数测试的黑色素瘤细胞系中的阴性对照相比,用 miR-26a 模拟物处理细胞系会导致显著且快速的细胞死亡。在调查 miR-26a 的靶标时,我们发现与对照相比,SMAD1(母亲抗 decapentaplegic 同源物 1)和 BAG-4/SODD 的蛋白水平在敏感细胞中用 miR-26a 模拟物处理时强烈降低。荧光素酶报告基因检测进一步表明,miR-26a 可以通过 SODD(死亡域沉默子)3'非翻译区 (3'UTR) 中的结合位点抑制基因表达。用小干扰 RNA (siRNA) 敲低这些蛋白显示,在大多数对 miR-26a 敏感的细胞系中,SODD 对于保护黑色素瘤细胞免于凋亡具有重要作用,而 SMAD1 可能具有较小的作用。此外,用 miR-26a 抑制剂转染细胞会增加 SODD 表达。我们的研究结果表明,miR-26a 替代是转移性黑色素瘤的潜在治疗策略,特别是 SODD 是一个潜在有用的治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/527ea0cb1a38/nihms410937f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/fb9f2cfc68a7/nihms410937f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/a40bba7e2f38/nihms410937f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/ed6f106e9dac/nihms410937f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/527ea0cb1a38/nihms410937f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/fb9f2cfc68a7/nihms410937f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/a40bba7e2f38/nihms410937f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/ed6f106e9dac/nihms410937f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cbaf/3898712/527ea0cb1a38/nihms410937f4.jpg

相似文献

1
MicroRNA-26a is strongly downregulated in melanoma and induces cell death through repression of silencer of death domains (SODD).微小 RNA-26a 在黑色素瘤中强烈下调,并通过抑制死亡结构域沉默子(SODD)诱导细胞死亡。
J Invest Dermatol. 2013 May;133(5):1286-93. doi: 10.1038/jid.2012.400. Epub 2012 Nov 29.
2
MicroRNAs as an emerging target for melanoma therapy.微小 RNA 作为黑素瘤治疗的新兴靶点。
J Invest Dermatol. 2013 May;133(5):1137-9. doi: 10.1038/jid.2012.505.
3
MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression.微小 RNA miR-196a 通过调节 HOX-C8 表达来控制黑色素瘤相关基因。
Int J Cancer. 2011 Sep 1;129(5):1064-74. doi: 10.1002/ijc.25768. Epub 2011 Feb 11.
4
Modulation of the Proliferation/Apoptosis Balance of Vascular Smooth Muscle Cells in Atherosclerosis by lncRNA-MEG3 via Regulation of miR-26a/Smad1 Axis.lncRNA-MEG3通过调控miR-26a/Smad1轴对动脉粥样硬化中血管平滑肌细胞增殖/凋亡平衡的调节作用
Int Heart J. 2019 Mar 20;60(2):444-450. doi: 10.1536/ihj.18-195. Epub 2019 Feb 8.
5
Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor.人脂肪组织来源干细胞的成骨分化受靶向SMAD1转录因子的miR-26a调控。
J Bone Miner Res. 2008 Feb;23(2):287-95. doi: 10.1359/jbmr.071011.
6
IL-10Rα expression is post-transcriptionally regulated by miR-15a, miR-185, and miR-211 in melanoma.在黑色素瘤中,IL-10Rα的表达受到miR-15a、miR-185和miR-211的转录后调控。
BMC Med Genomics. 2015 Dec 3;8:81. doi: 10.1186/s12920-015-0156-3.
7
MiRNA-26a Contributes to the Acquisition of Malignant Behaviors of Doctaxel-Resistant Lung Adenocarcinoma Cells through Targeting EZH2.微小RNA-26a通过靶向EZH2促进耐多西他赛肺腺癌细胞恶性行为的获得。
Cell Physiol Biochem. 2017;41(2):583-597. doi: 10.1159/000457879. Epub 2017 Feb 3.
8
LncRNA MIR205HG regulates melanomagenesis via the miR-299-3p/VEGFA axis.长链非编码 RNA MIR205HG 通过 miR-299-3p/VEGFA 轴调控黑色素瘤发生。
Aging (Albany NY). 2021 Feb 1;13(4):5297-5311. doi: 10.18632/aging.202450.
9
MiR-26a inhibits proliferation and apoptosis of uveal melanoma cells via regulating p53/MDM2 pathway.miR-26a 通过调控 p53/MDM2 通路抑制葡萄膜黑色素瘤细胞的增殖和凋亡。
J BUON. 2020 Sep-Oct;25(5):2476-2481.
10
miR-137 inhibits the invasion of melanoma cells through downregulation of multiple oncogenic target genes.miR-137 通过下调多个致癌靶基因抑制黑素瘤细胞的侵袭。
J Invest Dermatol. 2013 Mar;133(3):768-775. doi: 10.1038/jid.2012.357. Epub 2012 Nov 15.

引用本文的文献

1
Diagnostic Power of MicroRNAs in Melanoma: Integrating Machine Learning for Enhanced Accuracy and Pathway Analysis.微小RNA在黑色素瘤中的诊断能力:整合机器学习以提高准确性和通路分析
J Cell Mol Med. 2025 Jan;29(2):e70367. doi: 10.1111/jcmm.70367.
2
miR-15a targets the HSP90 co-chaperone Morgana in chronic myeloid leukemia.miR-15a 靶向慢性髓性白血病中的 HSP90 共伴侣 Morgana。
Sci Rep. 2024 Jul 2;14(1):15089. doi: 10.1038/s41598-024-65404-7.
3
Molecular Markers in Melanoma Progression: A Study on the Expression of miRNA Gene Subtypes in Tumoral vs. Benign Nevi.

本文引用的文献

1
ABT-737 synergizes with Bortezomib to kill melanoma cells.ABT-737 与硼替佐米协同作用杀死黑色素瘤细胞。
Biol Open. 2012 Feb 15;1(2):92-100. doi: 10.1242/bio.2011035. Epub 2011 Nov 16.
2
NF-κB as potential target in the treatment of melanoma.NF-κB 作为治疗黑色素瘤的潜在靶点。
J Transl Med. 2012 Mar 20;10:53. doi: 10.1186/1479-5876-10-53.
3
Targeting the Cellular Signaling: BRAF Inhibition and Beyond for the Treatment of Metastatic Malignant Melanoma.靶向细胞信号传导:BRAF抑制及其他治疗转移性恶性黑色素瘤的方法
黑色素瘤进展中的分子标志物:肿瘤性 vs. 良性痣中 miRNA 基因亚型表达的研究。
Curr Oncol. 2024 May 17;31(5):2881-2894. doi: 10.3390/curroncol31050220.
4
A New Approach to Melanoma Treatment: microRNAs.一种新的黑素瘤治疗方法:microRNAs。
Curr Top Med Chem. 2024;24(16):1362-1376. doi: 10.2174/0115680266291290240417081544.
5
Annexin A7 and Its Related Protein Suppressor of Death Domains Regulates Migration and Proliferation of Hca-P Cells.膜联蛋白A7及其相关蛋白死亡结构域抑制因子调节Hca-P细胞的迁移和增殖。
Cell J. 2023 Nov 1;25(11):801-808. doi: 10.22074/cellj.2023.559724.1108.
6
Human umbilical cord mesenchymal stem cells-derived exosomes exert anti-inflammatory effects on osteoarthritis chondrocytes.人脐带间充质干细胞来源的外泌体对骨关节炎软骨细胞具有抗炎作用。
Aging (Albany NY). 2023 Sep 18;15(18):9544-9560. doi: 10.18632/aging.205034.
7
SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling.SODD 通过激活 PDK1/AKT 和 RAF/MEK/ERK 信号促进肺癌肿瘤发生。
Genes (Basel). 2023 Mar 30;14(4):829. doi: 10.3390/genes14040829.
8
A Set of 17 microRNAs Common for Brain and Cerebrospinal Fluid Differentiates Primary Central Nervous System Lymphoma from Non-Malignant Brain Tumors.一组在大脑和脑脊液中都存在的 17 种 microRNAs 可将原发性中枢神经系统淋巴瘤与非恶性脑肿瘤区分开来。
Biomolecules. 2021 Sep 21;11(9):1395. doi: 10.3390/biom11091395.
9
MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.黑色素瘤中的微小RNA特征:生物标志物与治疗靶点
Front Oncol. 2021 Apr 22;11:608987. doi: 10.3389/fonc.2021.608987. eCollection 2021.
10
MicroRNAs at the Crossroad of the Dichotomic Pathway Cell Death vs. Stemness in Neural Somatic and Cancer Stem Cells: Implications and Therapeutic Strategies.微小 RNA 在二分路径细胞死亡与神经体干细胞和癌症干细胞干性之间的十字路口:意义和治疗策略。
Int J Mol Sci. 2020 Dec 17;21(24):9630. doi: 10.3390/ijms21249630.
Dermatol Res Pract. 2012;2012:259170. doi: 10.1155/2012/259170. Epub 2011 Dec 15.
4
MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein.微小 RNA-26a/b 及其宿主基因通过激活 pRb 蛋白合作抑制 G1/S 期转换。
Nucleic Acids Res. 2012 May;40(10):4615-25. doi: 10.1093/nar/gkr1278. Epub 2011 Dec 30.
5
MicroRNA regulation of melanoma progression.miRNA 对黑色素瘤进展的调控。
Melanoma Res. 2012 Apr;22(2):101-13. doi: 10.1097/CMR.0b013e32834f6fbb.
6
Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy.表观遗传学与遗传学。microRNAs 走向临床:验证和靶向 microRNAs 治疗癌症的进展。
Nat Rev Cancer. 2011 Nov 24;11(12):849-64. doi: 10.1038/nrc3166.
7
Non-coding RNAs in human disease.人类疾病中的非编码 RNA。
Nat Rev Genet. 2011 Nov 18;12(12):861-74. doi: 10.1038/nrg3074.
8
Potential applications of microRNAs in cancer diagnosis, prognosis, and treatment.微小 RNA 在癌症诊断、预后和治疗中的潜在应用。
Semin Oncol. 2011 Dec;38(6):781-7. doi: 10.1053/j.seminoncol.2011.08.007.
9
The three M's: melanoma, microphthalmia-associated transcription factor and microRNA.三个 M:黑色素瘤、小眼畸形相关转录因子和 microRNA。
Pigment Cell Melanoma Res. 2011 Dec;24(6):1088-106. doi: 10.1111/j.1755-148X.2011.00931.x.
10
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e.Jumonji/ARID1B(JARID1B)蛋白通过表观遗传抑制 microRNA let-7e 促进乳腺癌细胞周期进程。
J Biol Chem. 2011 Nov 25;286(47):40531-5. doi: 10.1074/jbc.M111.304865. Epub 2011 Oct 3.